AbbVie (ABBV) Looks to Deepen Its Push Into Rapidly Growing Obesity-Treatment Market

AbbVie Inc. (NYSE:ABBV) is one of the 10 Goldman Sachs undervalued stocks to invest in.

On January 14, 2026, Reuters reported that AbbVie Inc. (NYSE:ABBV) is looking to deepen its push into the rapidly growing obesity-treatment market, outlining its plans at the JPMorgan Healthcare Conference. The company’s plans center on GUBamy, an amylin-mimetic weight-loss drug licensed from Danish biotech Gubra. Emphasizing differentiation rather than a first-mover strategy, the company’s management highlighted that existing first-generation GLP-1 therapies pose problems related to tolerability and durability. These shortcomings drive high patient drop-off rates, management noted.

In contrast to GLP-1 drugs like Novo Nordisk’s Wegovy or Eli Lilly’s Zepbound, amylin-based therapies aim to replicate a pancreas-derived hormone that reduces appetite and slows gastric emptying. Furthermore, initial studies show that these drugs help preserve muscle mass while promoting weight loss. Thus, AbbVie Inc. (NYSE:ABBV) believes patients may be more likely to stay on treatment longer. Management appears optimistic about capitalizing on the market, projected to generate roughly $150 billion in annual sales over the next decade.

AbbVie Inc. (NYSE:ABBV) also aims to leverage the overlap between cosmetic and weight-loss patients on the back of its established aesthetics franchise. With this, the company could integrate care models for more efficient customer engagement.

AbbVie Inc. (NYSE:ABBV), a research-based biopharmaceutical company, develops therapies across immunology, oncology, neuroscience, virology, aesthetics, and metabolic diseases. The company leverages diversified pipelines and global commercialization capabilities, driving durable growth and innovation.

While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 7 Best Rising Tech Stocks to Buy Now and 12 Best Multibagger Stocks to Buy Heading into 2026.

Disclosure: None.